Washington’s Proposed China Crackdown Could Backfire on American Patients

MoneyMapPharmacy

America won’t maintain its pharmaceutical leadership by shutting itself off from promising discoveries abroad. Wherever the next breakthrough occurs, American companies should have the opportunity to help bring it to patients.

Several of the most exciting breakthroughs in cancer care are coming from China. New rules proposed by the Trump administration could make it harder for American patients to access those medicines.

On October 22, the Treasury Department proposed expanding restrictions on American investment in Chinese companies to include biotechnology. The proposal aims to prevent American capital and expertise from helping China develop technologies that could threaten U.S. national security.

That’s a legitimate concern. But there’s a world of difference between American investment that helps China develop weapons and investment that helps bring a promising cancer treatment to patients. Rules that fail to distinguish between the two could deprive Americans of new medicines while weakening our domestic pharmaceutical industry.

Read the op-ed here.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top